上海國資委調研上海醫藥 推動創新鏈產業鏈資金鍊人才鏈深度融合
內媒報道,上海市國資委黨委書記、主任賀青圍繞生物醫藥產業發展主題,赴上海醫藥集團(02607.HK)(601607.SH) 、上海生物醫藥基金開展專題調研,並與相關負責人座談交流,聽取近年來工作進展和未來戰略構想,共同研究推進下一步改革創新發展工作。
賀青對上海醫藥近年來堅持深耕主業、深化創新轉型、實現商業工業雙雙位居全國最前列給予充分肯定。賀青指出,上海醫藥作為上海生物醫藥產業「鏈主型」龍頭企業,要更好發揮產業引領作用,為上海現代化產業體系建設提供有力支撐。
未來做好工作包括:把握商業流通領域集中度不斷提高的趨勢,著力提升經營效率,穩妥開展投資併購,積極探索區塊鏈等新技術的創新應用,加快數字化轉型,提升供應鏈綜合價值,促進資源集聚,增強核心競爭力;要推動創新鏈產業鏈資金鍊人才鏈深度融合;要持續加大研發投入,加快新藥上市步伐。依託「雲天上」中醫藥產業聯盟推動中藥業務發展,鞏固提升在罕見病用藥市場的領先優勢。
賀青表示,上海市國資委將進一步完善賦能企業科技創新及優化產業佈局的制度供給,營造良好的幹事創業氛圍,全力支持上海醫藥及上海生物醫藥基金加快實現高質量發展。(ta/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.